NCT03836261: An ongoing trial by Acerta Pharma BV
This trial is ongoing. It must report results 2 years, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03836261 |
|---|---|
| Title | A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination With Venetoclax With and Without Obinutuzumab Compared to Investigator's Choice of Chemoimmunotherapy in Subjects With Previously Untreated Chronic Lymphocytic Leukemia Without Del(17p) or TP53 Mutation (AMPLIFY) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 25, 2019 |
| Completion date | Jan. 31, 2027 |
| Required reporting date | Jan. 31, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |